Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H34N2O7 |
| Molecular Weight | 450.5253 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC1=CC=C(CC2=C(C)N(N=C2O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C(C)C)C=C1
InChI
InChIKey=GSINGUMRKGRYJP-VZWAGXQNSA-N
InChI=1S/C23H34N2O7/c1-12(2)25-14(5)17(10-15-6-8-16(9-7-15)30-13(3)4)22(24-25)32-23-21(29)20(28)19(27)18(11-26)31-23/h6-9,12-13,18-21,23,26-29H,10-11H2,1-5H3/t18-,19-,20+,21-,23+/m1/s1
| Molecular Formula | C23H34N2O7 |
| Molecular Weight | 450.5253 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Remogliflozin is the active component of the pro-drug remogliflozin etabonate, which is used the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), is selective for SGLT2, which is responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice. | 2015-09 |
|
| Remogliflozin etabonate : a novel SGLT2 inhibitor for treatment of diabetes mellitus. | 2015-08-14 |
|
| Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus. | 2015 |
Sample Use Guides
Remogliflozin is the active component of the pro-drug remogliflozin etabonate. Using the ORAC assay, it was determined the antioxidant capacity of equal concentrations of remogliflozin etabonate, remogliflozin, canagliflozin and dapagliflozin. It was shown, remogliflozin displayed a robust antioxidant activity compared to the pro-drug and other SGLT2 inhibitors, canagliflozin and dapagliflozin.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:20:25 GMT 2025
by
admin
on
Mon Mar 31 20:20:25 GMT 2025
|
| Record UNII |
13ZPK7A4MJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
329045-45-6
Created by
admin on Mon Mar 31 20:20:25 GMT 2025 , Edited by admin on Mon Mar 31 20:20:25 GMT 2025
|
PRIMARY | |||
|
DTXSID30186563
Created by
admin on Mon Mar 31 20:20:25 GMT 2025 , Edited by admin on Mon Mar 31 20:20:25 GMT 2025
|
PRIMARY | |||
|
13ZPK7A4MJ
Created by
admin on Mon Mar 31 20:20:25 GMT 2025 , Edited by admin on Mon Mar 31 20:20:25 GMT 2025
|
PRIMARY | |||
|
9846588
Created by
admin on Mon Mar 31 20:20:25 GMT 2025 , Edited by admin on Mon Mar 31 20:20:25 GMT 2025
|
PRIMARY | |||
|
Remogliflozin
Created by
admin on Mon Mar 31 20:20:25 GMT 2025 , Edited by admin on Mon Mar 31 20:20:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PRODRUG -> METABOLITE ACTIVE |
|
